全文获取类型
收费全文 | 7193篇 |
免费 | 478篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 212篇 |
妇产科学 | 193篇 |
基础医学 | 1214篇 |
口腔科学 | 164篇 |
临床医学 | 664篇 |
内科学 | 1513篇 |
皮肤病学 | 286篇 |
神经病学 | 681篇 |
特种医学 | 244篇 |
外科学 | 623篇 |
综合类 | 45篇 |
一般理论 | 3篇 |
预防医学 | 673篇 |
眼科学 | 67篇 |
药学 | 518篇 |
中国医学 | 26篇 |
肿瘤学 | 531篇 |
出版年
2023年 | 51篇 |
2022年 | 28篇 |
2021年 | 159篇 |
2020年 | 165篇 |
2019年 | 208篇 |
2018年 | 219篇 |
2017年 | 166篇 |
2016年 | 202篇 |
2015年 | 234篇 |
2014年 | 289篇 |
2013年 | 371篇 |
2012年 | 569篇 |
2011年 | 564篇 |
2010年 | 323篇 |
2009年 | 265篇 |
2008年 | 466篇 |
2007年 | 486篇 |
2006年 | 465篇 |
2005年 | 435篇 |
2004年 | 364篇 |
2003年 | 352篇 |
2002年 | 308篇 |
2001年 | 90篇 |
2000年 | 69篇 |
1999年 | 63篇 |
1998年 | 65篇 |
1997年 | 48篇 |
1996年 | 45篇 |
1995年 | 38篇 |
1994年 | 28篇 |
1993年 | 25篇 |
1992年 | 35篇 |
1991年 | 37篇 |
1990年 | 35篇 |
1989年 | 22篇 |
1988年 | 27篇 |
1987年 | 22篇 |
1986年 | 29篇 |
1985年 | 25篇 |
1984年 | 12篇 |
1983年 | 15篇 |
1982年 | 22篇 |
1981年 | 22篇 |
1979年 | 17篇 |
1978年 | 16篇 |
1977年 | 14篇 |
1976年 | 15篇 |
1974年 | 13篇 |
1971年 | 14篇 |
1968年 | 12篇 |
排序方式: 共有7691条查询结果,搜索用时 31 毫秒
71.
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. 总被引:4,自引:0,他引:4
K Vera L Djafari S Faivre J-S Guillamo K Djazouli M Osorio F Parker C Cioloca B Abdulkarim J-P Armand E Raymond 《Annals of oncology》2004,15(1):161-171
BACKGROUND: Temozolomide has shown activity and limited toxicity in patients with primary brain tumors at doses of 150-200 mg/m(2)/day on days 1-5 every 4 weeks. In this study, a new alternative dose-dense regimen of temozolomide was explored in patients with recurrent brain tumors. PATIENTS AND METHODS: In this study, we evaluated the safety, dose-limiting toxicity, maximum tolerated dose, recommended dose and activity of temozolomide given on days 1-3 and 14-16 every 28 days (one cycle). The starting daily dose was 200 mg/m(2) in a group of at least six patients, with subsequent increments of 50 mg/m(2) in groups of at least 12 patients until unacceptable toxicity was reached. Oral ondansetron (8 mg) was given 1 h prior to temozolomide administration. McDonald's criteria were used to evaluate antitumor activity. RESULTS: Seventy patients with brain tumors entered this study. The median number of prior chemotherapy treatments was two (range 1-3). Patients were assigned to one of four groups to receive temozolomide at daily doses of 200 (seven patients), 250 (13 patients), 300 (38 patients) and 350 mg/m(2)/day (12 patients). The absence of dose-limiting toxicity at cycle 1 led us to establish dose recommendations based on toxicity after repeated cycles. A total of 23, 72, 192 and 83 cycles were given at daily doses of 200, 250, 300 and 350 mg/m(2), respectively. Grade 3-4 thrombocytopenia was observed in 0/7, 1/13, 5/38 and 4/12 patients treated at doses of 200, 250, 300 and 350 mg/m(2)/day, respectively. Grade 3-4 neutropenia was observed in 1/7, 0/13, 3/38 and 4/12 patients treated with 200, 250, 300 and 350 mg/m(2)/day temozolomide, respectively. At a dose of 350 mg/m(2), sustained grade 2-3 thrombocytopenia did not allow treatment to be resumed at day 14 in >40% of patients, and this dose was considered to be the maximum tolerated dose. Thus, a dose of 300 mg/m(2)/day that was associated with <20% treatment delay due to sustained hematological toxicity was considered as the recommended dose. Objective responses were reported in 13 patients. CONCLUSIONS: Temozolomide can be given safely using a dose-dense regimen of 300 mg/m(2)/day for 3 consecutive days every 2 weeks in patients with recurrent brain tumors. 相似文献
72.
Expression and activity of CYP2E1 in circulating lymphocytes are not altered in diabetic individuals
Laura Pucci Vera Chirulli Sandra Marini Daniela Lucchesi Giuseppe Penno Pier Giovanni Gervasi Stefano Del Prato Vincenzo Longo 《Pharmacological research》2005,51(6):561-565
Cytochrome P4502E1 (CYP2E1) plays an important role in ROS production thus favouring accelerated membrane lipid peroxidation. This isoform is strongly expressed in the liver but it can be also found in lymphocytes. As such, lymphocyte may provide a non-invasive accessible pool for screening CYP2E1 expression in man. We have, therefore, analysed CYP2E1 expression and activity in lymphocyte microsomes from 12 healthy controls, 11 type 1 and 12 type 2 diabetic subjects by using Western blot and enzymatic activities. Immunoblotting did not show difference among CYP2E1 protein bands in controls, type 1 and type 2 diabetics. To assess CYP2E1 activity we used the 7-ethoxy-4-trifluoromethylcoumarin (7-EFC), as a fluorescent substrate. The rate of deethylation of 7-EFC from controls did not differ from type 1 and type 2 diabetic subjects. The lack of any difference in CYP2E1 activity also was confirmed by the NADPH-dependent microsomal lipid peroxidation CCL4-induced assay showing similar peroxidation rates among controls and diabetic subjects. The results show that CYP2E1 expression/activity in lymphocytes is not enhanced in diabetes. 相似文献
73.
Fernando Arias de la Vega Miguel Angel Domínguez Domínguez Ana Manterola Burgaleta Ruth Vera García Maria Eugenia Echeverría Zabalza Eugenio Oria Mundin Enrique Martínez López Pilar Romero Rojano Elena Villafranca Iture 《Clinical & translational oncology》2005,7(2):60-65
INTRODUCTION: This study aims to asses the effectiveness and toxicity of boost radiotherapy concomitant and concurrent cisplatin for patients with locally advanced head and neck cancer (LAHNC). MATERIAL AND METHODS: There were 30 patients included in a prospective, phase II single-institution trial and of whom, 29 were at AJCC stage IV and 1 at stage III. Treatment consisted of radiotherapy acceleration fractionation with concomitant boost, 72 Gy, and 2 cycles of concomitant cisplatin (20 mg/m2/day continuous infusion; days 1-5 and 29-33). Amifostine, (i.v. 200 mg/m2) was administered to 26 prior to the first fraction of radiotherapy. Endpoints of the study were quality-of-life (QL), overall survival, and local control of disease. RESULTS: Complete response (CR) was achieved in 23 patients (77%), 2 patients had partial response (PR) (7%), 4 had no response (13%), and 1 was not evaluated for response. The 2-year overall survival and loco-regional control were 60% and 56%, respectively. Main toxicity was grade 3 or 4 mucositis in 93% of the patients. QL scores (questionnaire QLQC30; version 3.0) and the HN cancer module QLQ-HN35) showed a worsening in areas related to the treatment e.g. dry mouth, problems stretching the mouth, and sticky saliva. CONCLUSIONS: this combination modality is active, but toxic, in the treatment for LAHNC. Concomitant boost radiotherapy is probably, not the best radiotherapy schema for combining with chemotherapy in LAHNC. 相似文献
74.
Pascale De Paepe Ruth Achten Gregor Verhoef Iwona Wlodarska Michel Stul Vera Vanhentenrijk Marleen Praet Chris De Wolf-Peeters 《Journal of clinical oncology》2005,23(28):7060-7068
PURPOSE: The reliability of immunohistochemistry for subdividing diffuse large B-cell lymphomas (DLBCL) into germinal center B-cell-like (GCB) and non-GCB prognostic subgroups is debated. In this study we evaluated the prognostic significance of such subgrouping on a series of 153 DLBCL patients. Furthermore, we investigated whether both subgroups could comprise clinicopathologic entities recognized by their morphology and characterized by a distinct phenotype, specific genetic abnormalities, and clinical characteristics. PATIENTS AND METHODS: All samples from patients were reviewed and morphologically subdivided into large cleaved, immunoblastic, and not otherwise specified DLBCL. GCB and non-GCB immunohistochemical profiles were established. The presence of chromosomal translocations involving BCL2, BCL6, and MYC and/or rearrangements of these genes was investigated. RESULTS: Subdividing DLBCL with either a GCB or non-GCB immunophenotypic profile was not of prognostic significance. Nevertheless, CD10 expression was a predictor of favorable outcome, whereas high bcl-2 expression and BCL6 rearrangement were adverse predictors of disease-free survival. Interestingly, large cleaved DLBCL was clearly associated with a GCB immunophenotypic profile, CD10 expression, BCL2 rearrangement, age younger than 60 years, and low to low/intermediate International Prognostic Index risk, but was not of prognostic significance. In contrast, immunoblastic morphology was associated with a non-GCB profile and was a significant predictor of unfavorable DFS. CONCLUSION: Subdividing DLBCL into subgroups based on their immunohistochemical profile was not of prognostic significance. Nevertheless, it allowed the additional characterization of two lymphoma subgroups previously recognized in the Working Formulation. Both correspond to two distinct clinicopathologic entities within the DLBCL. 相似文献
75.
76.
77.
Agreeing with Damasio’s statement defining the “process” of consciousness, we propose the self as created by mind-based knowledge and a combination of images of an organism’s intentional motor responses interacting with its environment. The lemniscal system, with plastic capabilities, manages gravity in voluntary movement. The spinal segment motor reflex represents the schema of gravity-managing neuronal activity, and it can become “nested” in cortical areas participating in consciousness-building, allowing consideration of the brain as a hyper-evolved nervous system segment harboring atavic spinal organization. Consciousness’ capability to change itself makes humans co-participants in their own mental and consciousness evolution. 相似文献
78.
Conrad P. Quinn Carol L. Sabourin Nancy A. Niemuth Han Li Vera A. Semenova Thomas L. Rudge Heather J. Mayfield Jarad Schiffer Robert S. Mittler Chris C. Ibegbu Jens Wrammert Rafi Ahmed April M. Brys Robert E. Hunt Denyse Levesque James E. Estep Roy E. Barnewall David M. Robinson Brian D. Plikaytis Nina Marano 《Clinical and Vaccine Immunology : CVI》2012,19(11):1730-1745
A 3-dose (0, 1, and 6 months) intramuscular (3-IM) priming series of a human dose (HuAVA) and dilutions of up to 1:10 of anthrax vaccine adsorbed (AVA) provided statistically significant levels of protection (60 to 100%) against inhalation anthrax for up to 4 years in rhesus macaques. Serum anti-protective antigen (anti-PA) IgG and lethal toxin neutralization activity (TNA) were detectable following a single injection of HuAVA or 1:5 AVA or following two injections of diluted vaccine (1:10, 1:20, or 1:40 AVA). Anti-PA and TNA were highly correlated (overall r2 = 0.89 for log10-transformed data). Peak responses were seen at 6.5 months. In general, with the exception of animals receiving 1:40 AVA, serum anti-PA and TNA responses remained significantly above control levels at 28.5 months (the last time point measured for 1:20 AVA), and through 50.5 months for the HuAVA and 1:5 and 1:10 AVA groups (P < 0.05). PA-specific gamma interferon (IFN-γ) and interleukin-4 (IL-4) CD4+ cell frequencies and T cell stimulation indices were sustained through 50.5 months (the last time point measured). PA-specific memory B cell frequencies were highly variable but, in general, were detectable in peripheral blood mononuclear cells (PBMC) by 2 months, were significantly above control levels by 7 months, and remained detectable in the HuAVA and 1:5 and 1:20 AVA groups through 42 months (the last time point measured). HuAVA and diluted AVA elicited a combined Th1/Th2 response and robust immunological priming, with sustained production of high-avidity PA-specific functional antibody, long-term immune cell competence, and immunological memory (30 months for 1:20 AVA and 52 months for 1:10 AVA). Vaccinated animals surviving inhalation anthrax developed high-magnitude anamnestic anti-PA IgG and TNA responses. 相似文献
79.
Ben Davidson Vera Maria Abeler Ellen Hellesylt Arild Holth Ie-Ming Shih Tone Skeie-Jensen Li Chen Yanqin Yang Tian-Li Wang 《Gynecologic oncology》2013,128(2):349-355
ObjectiveEndometrial stromal sarcoma (ESS) and leiomyosarcoma (LMS) are the two most common uterine sarcomas, but both are rare tumors. The aim of the present study was to compare the global gene expression patterns of ESS and LMS.MethodsGene expression profiles of 7 ESS and 13 LMS were analyzed using the HumanRef-8 BeadChip from Illumina. Differentially expressed candidate genes were validated using quantitative real-time PCR and immunohistochemistry.ResultsUnsupervised hierarchical clustering using all 54,675 genes in the array separated ESS from LMS samples. We identified 549 unique probes that were significantly differentially expressed in the two malignancies by greater than 2-fold with 1% FDR cutoff using one-way ANOVA with Benjamini–Hochberg correction, of which 336 and 213 were overexpressed in ESS and LMS, respectively. Genes overexpressed in ESS included SLC7A10, EFNB3, CCND2, ECEL1, ITM2A, NPW, PLAG1 and GCGR. Genes overexpressed in LMS included CDKN2A, FABP3, TAGLN, JPH2, GEM, NAV2 and RAB23. The top 100 genes overexpressed in LMS included those coding for myosin light chain and caldesmon, but not the genes coding for desmin or actin. CD10 was not overexpressed in ESS. Results for selected genes were validated by quantitative real-time PCR and immunohistochemistry.ConclusionsWe present the first study in which gene expression profiling was shown to distinguish between ESS and LMS. The molecular signatures unique to each of these malignancies may aid in expanding the diagnostic battery for their differentiation, and may provide a molecular basis for prognostic studies and therapeutic target discovery. 相似文献
80.
Goldie Y.L. Lui Zaklina Kovacevic Vera Richardson Angelica M. Merlot Danuta S. Kalinowski Des R. Richardson 《Oncotarget》2015,6(22):18748-18779
Newer and more potent therapies are urgently needed to effectively treat advanced cancers that have developed resistance and metastasized. One such strategy is to target cancer cell iron metabolism, which is altered compared to normal cells and may facilitate their rapid proliferation. This is supported by studies reporting the anti-neoplastic activities of the clinically available iron chelators, desferrioxamine and deferasirox. More recently, ligands of the di-2-pyridylketone thiosemicarbazone (DpT) class have demonstrated potent and selective anti-proliferative activity across multiple cancer-types in vivo, fueling studies aimed at dissecting their molecular mechanisms of action. In the past five years alone, significant advances have been made in understanding how chelators not only modulate cellular iron metabolism, but also multiple signaling pathways implicated in tumor progression and metastasis. Herein, we discuss recent research on the targeting of iron in cancer cells, with a focus on the novel and potent DpT ligands. Several key studies have revealed that iron chelation can target the AKT, ERK, JNK, p38, STAT3, TGF-β, Wnt and autophagic pathways to subsequently inhibit cellular proliferation, the epithelial-mesenchymal transition (EMT) and metastasis. These developments emphasize that these novel therapies could be utilized clinically to effectively target cancer. 相似文献